Literature DB >> 8751825

Study of the role of iron in the anticryptococcal activity of human serum and fluconazole.

D D Grover1, E Brummer, D A Stevens.   

Abstract

Anticryptococcal activity of human serum and apotransferrin in RPMI 1640 was studied in vitro. The effects of varying concentrations of FeCl3 on this activity was investigated. Possible synergy of serum and apotransferrin with fluconazole was also measured. The fungistatic activity of human serum, whether lyophilized, stored at 4 degrees C, fresh frozen or purchased from commercial sources vs. Cryptococcus neoformans was comparable. There was no significant loss of fungistatic activity after freezing and thawing the serum up to 10 times. The fungistatic activity of human serum was similar when tested in different tissue culture media with the exception of Medium 199. The addition of apotransferrin (2.0 or 0.2 mg/ml) to RPMI 1640 had an inhibitory effect on cryptococcal growth. This effect was reversed by 20 microM, of FeCl3 at both apotransferrin concentrations. By contrast, addition of FeCl3 to human serum and RPMI 1640 did not reverse inhibition of growth. Fluconazole synergized with the human serum preparations described, but not with pooled commercial serum, for fungicidal activity. Synergistic activity of fluconazole and human serum was not affected by the addition of FeCl3. Apotransferrin did not show any synergistic fungicidal activity with fluconazole.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8751825     DOI: 10.1007/bf00439116

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  7 in total

1.  CHARACTERIZATION OF THE GROWTH INHIBITION FACTOR FOR CRYPTOCOCCUS NEOFORMANS (GIFC) IN HUMAN SERUM.

Authors:  G L BAUM; D ARTIS
Journal:  Am J Med Sci       Date:  1963-07       Impact factor: 2.378

2.  Cryptococcosis and AIDS.

Authors: 
Journal:  Lancet       Date:  1988-06-25       Impact factor: 79.321

3.  The anticryptococcal factor of blood serum. A preliminary report.

Authors:  G Szilagyi; F Reiss; J C Smith
Journal:  J Invest Dermatol       Date:  1966-03       Impact factor: 8.551

4.  Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans.

Authors:  H J Igel; R P Bolande
Journal:  J Infect Dis       Date:  1966-02       Impact factor: 5.226

5.  The relationship of transferrin and iron to serum inhibition of Candida albicans.

Authors:  N B Esterly; S R Brammer; R G Crounse
Journal:  J Invest Dermatol       Date:  1967-11       Impact factor: 8.551

6.  Some factors which affect the initiation of growth of Cryptococcus neoformans.

Authors:  D H HOWARD
Journal:  J Bacteriol       Date:  1961-09       Impact factor: 3.490

7.  Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity.

Authors:  F Nassar; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

  7 in total
  1 in total

1.  Characterization of an anticryptococcal protein isolated from human serum.

Authors:  S Sridhar; M Ahluwalia; E Brummer; D A Stevens
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.